Daré regains Nasdaq minimum bid price compliance, delisting risk removed

Dare Bioscience, Inc.

Nasdaq notified Daré that closing bid price was ≥$1.00 for 10 consecutive sessions; compliance achieved.
Regaining compliance avoids potential delisting from Nasdaq Capital Market, strengthening market position.
Enrolling participants in pivotal Phase 3 study of Ovaprene for hormone-free monthly contraceptive candidate.
Continuing activities to progress Sildenafil Cream 3.6% Phase 3 pivotal studies for female sexual arousal disorder.
Awaiting additional FDA feedback on endpoints and safety database requirements for NDA submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.